Advertisement

WAT

Waters Corporation

Healthcare · USD

Set alert

Price alert · WAT

All alert types
462.72 USD -17.35 -3.61%
As of Oct 30, 2026 Extended hours 462.72 0.00%
Bid
462.58 × 40
Ask
462.71 × 160
458.85 Day range 479.60
283.32 52-week range 480.07
YTD
+21.82%
1 year
+34.94%
Open
479.04
Prev close
480.07
Mkt cap
45.43B
Vol
1.34M
Avg vol
803.65K
EPS
3.95
P/E
117.14
Div yield
0.00%
More statistics
Low
458.85
High
479.60
Forward P/E
27.96
Beta
1.15
Short ratio
3.72
Inst. own
102.21%
Dividend
0.00
Ex-div date
Nov 25, 1996
Earnings
Nov 3, 2026
50-d avg
429.02
200-d avg
369.17
1y target
465.86

5D chart

Chart tools
Interval
WAT five-day price chart449.9458.0466.1474.2482.3Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
45.43B
Enterprise value
52.10B
Trailing P/E
117.15
Forward P/E
27.96
PEG ratio
1.79
Price / sales
9.78
Price / book
2.99
EPS (TTM)
3.95
Beta
1.15
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
3.59%
Revenue (TTM)
4.64B
Revenue growth
113.40%
Free cash flow
-142.07M
Total cash
539.00M
Total debt
5.48B
Return on equity
1.92%
Shares outstanding
98.19M
Short % of float
3.25%
50-day average
429.02
200-day average
369.17

Analyst view

Consensus: buy

Buy
Price target (mean) 465.86 +0.7% upside
Target (low)
349.00
Target (mean)
465.86
Target (high)
530.00
Ratings (0m) 23 18 buy · 4 hold · 1 sell
  • Strong buy3
  • Buy15
  • Hold4
  • Sell0
  • Strong sell1

Next earnings

Nov 3, 2026

Expected Nov 3, 2026. Consensus EPS estimate 4.00.

Earnings history

Financials — quick view

All financials
WAT Revenue — quarterly 1.65B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
WAT Net income — quarterly -136.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
WAT EPS — quarterly -1.39
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

WAT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 3, 2026Oct 4, 20264.00———
Aug 4, 2026Jul 4, 20263.013.05+0.04+1.33%
May 5, 2026Apr 4, 20262.312.70+0.39+16.88%
Feb 9, 2026Dec 31, 20254.514.53+0.02+0.44%
Nov 4, 2025Sep 27, 20253.213.40+0.19+5.92%
Aug 4, 2025Jun 28, 20252.942.95+0.01+0.34%

Upgrades / downgrades

WAT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026TD CowenmainBuyBuy
Oct 7, 2026BarclaysmainOverweightOverweight
Oct 1, 2026GuggenheimmainBuyBuy
Sep 21, 2026Goldman SachsmainBuyBuy
Sep 9, 2026UBSupNeutralBuy
Aug 27, 2026Piper SandlerupNeutralOverweight

About Waters Corporation

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
waters.com

News

Your note

Sign in to keep a note on WAT — it syncs with the Stock Master app.

Insider holders

WAT insider holders
InsiderRelationLatest transactionDateShares held
BATRA UDITChief Executive OfficerStock Award(Grant)Feb 24, 202636,557
BENNETT JIANQINGOfficerStock Award(Grant)Feb 24, 20267,244
CARPIO ROBERT L IIIOfficerStock Award(Grant)Feb 24, 20263,615
CHAUBAL AMOLChief Financial OfficerStock Award(Grant)Feb 24, 20268,505
FEARON RICHARD HDirectorPurchaseMar 5, 20263,302
HUANG PEARL S.DirectorStock Award(Grant)Feb 24, 20263,276

Institution ownership

WAT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.64%8,484,9393.93BJun 29, 2026
Vanguard Capital Management LLC6.53%6,415,5522.97BJun 29, 2026
Vanguard Portfolio Management LLC4.83%4,740,5242.19BJun 29, 2026
Massachusetts Financial Services Co.4.71%4,625,0352.14BJun 29, 2026
State Street Corporation4.46%4,382,0082.03BJun 29, 2026
T. Rowe Price Investment Management, Inc.3.89%3,817,7791.77BJun 29, 2026

Fund ownership

WAT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%3,116,3401.44BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%2,545,4191.18BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.17%2,127,547984.47MJun 29, 2026
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App2.14%2,101,625972.47MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%1,309,174605.79MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%1,274,542589.76MAug 30, 2026
Advertisement